Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 263.55B P/E 35.15 EPS this Y -2.10% Ern Qtrly Grth -32.30%
Income 5.3B Forward P/E 13.52 EPS next Y 11.10% 50D Avg Chg 8.00%
Sales 55B PEG 2.89 EPS past 5Y 3.71% 200D Avg Chg -1.00%
Dividend 4.00% Price/Book 19.85 EPS next 5Y 6.26% 52W High Chg -11.00%
Recommedations 2.10 Quick Ratio 0.59 Shares Outstanding 1.77B 52W Low Chg 14.00%
Insider Own 0.10% ROA 7.94% Shares Float 1.76B Beta 0.62
Inst Own 73.39% ROE 54.26% Shares Shorted/Prior 17.79M/20.19M Price 149.38
Gross Margin 69.66% Profit Margin 9.71% Avg. Volume 5,937,400 Target Price 197.33
Oper. Margin 34.56% Earnings Date Oct 30 Volume 5,753,546 Change 0.57%
About AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc. News
10:03 AM 4 Big Drug Stocks That May Continue to Outperform in 2025
08:00 AM AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
12/16/24 AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
12/16/24 ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?
12/16/24 ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
12/16/24 EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease
12/16/24 AbbVie to acquire Nimble Therapeutics for $200m
12/16/24 3 closely watched drugs that failed in the clinic
12/15/24 Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
12/13/24 This Drugmaker's (ABBV) Parkinson's Medication Just Cleared A Key Hurdle – Is It Primed For A Monster Year In 2025?
12/13/24 AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
12/13/24 AbbVie to acquire Roche spinout Nimble in immune drug deal
12/12/24 Why AbbVie Inc. (ABBV) Is the Best Safe Stock to Buy According to Analysts?
12/12/24 1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever
12/11/24 AbbVie Completes Acquisition of Aliada Therapeutics
12/11/24 BenevolentAI restructures; Lilly preps $15B buyback program
12/10/24 Why Is AbbVie Inc. (ABBV) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?
12/10/24 AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal
12/10/24 AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year
12/10/24 AbbVie’s Phase III trial of Parkinson’s disease treatment meets primary endpoint
ABBV Chatroom

User Image TwoBengalsCapital Posted - 1 hour ago

@Toni19 @Itsybitsybeanbag we are just seeing the last of Hedgies shenanigans they need to unload their competitors shares at premium while they load up on $RVPH, would you still want to be holding $ABBV $ITCI or $BMY when brilaroxazine sees a 50pt drop in PANSS at one year with little side effects. This is a threat level molecule with this level of efficacy, they all misread Reviva against Cereval and Neurocrines failed new MOA molecules. Even though this is another partial agonist we know this MOA works , what hasn’t worked is the patient’s willingness to take and stay on the current medications due to side effects (mostly due to the CYP3A4 enzyme pathway used, eliminating efficacy within whole demographics such as the asian population, which this does not and has shown in the trial patients race, hence when you look at the current approved atypical clinical trials they all have limited asian population data)

User Image cb5000calls Posted - 5 hours ago

$SLS how many more failures from $MRK and $RHHBY and $ABBV before our POS MM allows this return to a realistic market cap given the progression we've seen to date. Any other biotech with a Phase 3 Interiam Analysis and likely halt coming up this January would easily be valued at $1 billion espcially when they are sitting on 3 Priority Review Vouchers, so many FDA designations, and an entire other pipeline with SLS009 with best in class CDK9 inhbitors. Makes no sense for this to continue being manipulated this low.

User Image Botsrobot Posted - 6 hours ago

$ABBV IS GOING TO FLY THIS WEEK!! LOTS OF BUYING IN AFTER HOURS!

User Image LiveTradePro Posted - 6 hours ago

$ABBV Bullish engulfing candlestick Looks like this may well have found bottom I have calls from yesterday Added more on the pullback today $174(ish) https://share.trendspider.com/chart/ABBV/6682sz654p

User Image MontanaT Posted - 6 hours ago

$ABBV 200+

User Image cea Posted - 8 hours ago

$SLS If you do not have direct knowledge, @GoldenEyeWatcher, yet you communicate insider information, you are guilty of criminal SEC violations. If you’d said I believe we will see an offer from big pharma on Friday, that would be one thing. But you are specific in referencing $ABBV and a specific price. Me thinks you dissemble too much. What was your previous handle on ST? @Alyssa_CC

User Image fishinNbanjo Posted - 8 hours ago

$ABBV its crazy how awful this thing is even with an upgrade and price target increase

User Image Stockfinesser20 Posted - 9 hours ago

https://www.investing.com/news/analyst-ratings/abbvie-shares-price-target-lifted-rating-held-on-strong-drug-outlook-93CH-3777481 $ABBV

User Image cea Posted - 9 hours ago

$SLS $ABBV @GoldenEyeWatcher There is no objective evidence that Abbive has made such an offer. If you are privy to insider information, don’t share here and involve the rest of us in possible SEC violations. I also note you have not included the Abbive board in your communications; I’ve rectified this lapse. If anyone from the $ABBV board could comment, it would be appreciated. Make note that @GoldenEyeWatcher has made this claim and no one on the $SLS board has had anything to do with creation of this assertion.

User Image fishinNbanjo Posted - 10 hours ago

$ABBV man, i guess it's going red here. Healthcare is so hated

User Image fishinNbanjo Posted - 10 hours ago

$ABBV my god. This thing is a complete joke.

User Image fishinNbanjo Posted - 10 hours ago

$ABBV won't surprise me if this goes red

User Image HalimM23 Posted - 10 hours ago

$ABBV

User Image cubie Posted - 11 hours ago

$TGT $ABBV do what abbv did indeed🫡😏

User Image middleman Posted - 11 hours ago

$ABBV hell yeah

User Image BigPennyHits Posted - 12 hours ago

$ABBV on custom call options scanner 20 Dec 24 $182.50 .19-.21 Follow along for more custom scan alerts Not financial advice

User Image fishinNbanjo Posted - 12 hours ago

$ABBV wow, heading higher

User Image Adamip Posted - 12 hours ago

$ABBV why are we up? Is there news?

User Image 0xTrader Posted - 12 hours ago

$ABBV 🤘

User Image Gramma Posted - 12 hours ago

$ABBV yeah!!!

User Image LiveTradePro Posted - 12 hours ago

Getting some nice bounces here on select stocks like $ABBV I have calls https://share.trendspider.com/chart/ABBV/6682slayww

User Image PAPABULLBEARDsolo94 Posted - 12 hours ago

$ABBV needs to go down lol

User Image PAPABULLBEARDsolo94 Posted - 12 hours ago

$ABBV ehat is you doing

User Image fishinNbanjo Posted - 12 hours ago

$ABBV wow, switched to bullish. Nice

User Image fishinNbanjo Posted - 13 hours ago

$ABBV fing finally

User Image fishinNbanjo Posted - 14 hours ago

$ABBV worse everyday

User Image Article_AI Posted - 14 hours ago

$ABBV AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back? AbbVie has a lofty goal for 2025 — and a big move in cancer treatment could stoke beleaguered AbbVie stock. The post AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. https://www.stck.pro/news/ABBV/96396815/

User Image Stockfinesser20 Posted - 14 hours ago

$ABBV oversold. Huge upside here

User Image fishinNbanjo Posted - 16 hours ago

$ABBV well, looks like yet another red day.

User Image seeitmarket Posted - 1 day ago

NEW Article: “Why Investors Should Watch AbbVie Inc (ABBV)” - https://www.seeitmarket.com/why-investors-should-watch-abbvie-inc-abbv/ by @marketminute $SPY $XLV $XBI $ABBV

Analyst Ratings
Piper Sandler Overweight Aug 23, 24
Morgan Stanley Overweight Aug 12, 24
Cantor Fitzgerald Overweight Aug 5, 24
Cantor Fitzgerald Overweight Jul 26, 24
Truist Securities Buy Jul 26, 24
Wells Fargo Overweight Jul 26, 24
Barclays Overweight Jul 26, 24
BMO Capital Outperform Jul 19, 24
Morgan Stanley Overweight Jul 11, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Donoghoe Nicholas EVP, CHIEF BUS/STRAT.. EVP, CHIEF BUS/STRAT OFFICER Dec 26 Sell 154.72 2,912 450,545 55,903 12/28/23
GONZALEZ RICHARD A CHAIRMAN OF THE BOAR.. CHAIRMAN OF THE BOARD AND CEO Jul 31 Sell 148.87 78,500 11,686,295 565,294 08/02/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Apr 17 Sell 161.84 7,499 1,213,638 35,330 04/19/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 28 Sell 155 15,003 2,325,465 42,829 03/02/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 28 Option 93.5 15,003 1,402,780 57,832 03/02/23
Siatis Perry C EVP, GC AND SECRETAR.. EVP, GC AND SECRETARY Feb 28 Sell 153.22 12,135 1,859,325 10,377 03/02/23
Strom Carrie C SVP & PRES GLOBAL AL.. SVP & PRES GLOBAL ALLERG AESTH Feb 16 Sell 151.02 28,541 4,310,262 37,921 02/21/23
Strom Carrie C SVP & PRES GLOBAL AL.. SVP & PRES GLOBAL ALLERG AESTH Feb 16 Option 62.09 14,179 880,374 66,462 02/21/23
SALEKI-GERHARDT AZITA EVP, OPERATIONS EVP, OPERATIONS Feb 16 Option 51.42 25,000 1,285,500 258,208 02/21/23
SALEKI-GERHARDT AZITA EVP, OPERATIONS EVP, OPERATIONS Feb 16 Sell 149.59 25,000 3,739,750 233,208 02/21/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 16 Sell 151.02 15,321 2,313,777 62,679 02/21/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 16 Option 105.92 15,321 1,622,800 78,000 02/21/23
SEVERINO MICHAEL Vice Chairman Vice Chairman May 23 Option 104.59 79,801 8,346,387 231,904 05/25/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 23 Sell 151.16 79,801 12,062,719 152,103 05/25/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer May 16 Option 54.86 83,960 4,606,046 125,583 05/20/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer May 16 Sell 155 83,960 13,013,800 41,623 05/20/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 16 Option 78.23 200,000 15,646,000 252,103 05/18/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 16 Sell 154.58 200,000 30,916,000 152,103 05/18/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 06 Sell 151.2 300,000 45,360,000 152,103 05/10/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 06 Option 57.21 300,000 17,163,000 252,103 05/10/22
Stewart Jeffrey Ryan EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 24 Option 58.88 27,690 1,630,387 88,631 03/25/22
Stewart Jeffrey Ryan EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 24 Sell 159.2 27,690 4,408,248 60,941 03/25/22
Durkin Brian L VP, Controller VP, Controller Mar 09 Option 79.02 11,682 923,112 37,722 03/11/22
Durkin Brian L VP, Controller VP, Controller Mar 09 Sell 150 18,628 2,794,200 19,094 03/11/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer Mar 01 Sell 148.12 25,000 3,703,000 16,623 03/02/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer Feb 25 Sell 148.43 15,000 2,226,450 41,623 03/01/22
Michael Robert A. Vice Chairman Vice Chairman Feb 25 Sell 148.32 43,105 6,393,334 37,877 03/01/22
Strom Carrie C SVP & Pres Global Al.. SVP & Pres Global Allerg Aesth Feb 07 Sell 141.17 2,396 338,243 42,499 02/08/22
AUSTIN ROXANNE S Director Director Nov 02 Sell 116.42 71,844 8,364,078 49,284 11/04/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Aug 25 Sell 120 13,080 1,569,600 11,595 08/25/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Aug 25 Option 114.36 7,080 809,669 18,675 08/25/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Feb 24 Option 86.26 20,195 1,742,021 52,946 02/24/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Feb 24 Sell 105 20,195 2,120,475 32,751 02/24/21
RICHMOND TIMOTHY J. EVP, Chief HR Office.. EVP, Chief HR Officer Dec 01 Option 51.42 51,990 2,673,326 51,990 12/01/20
RICHMOND TIMOTHY J. EVP, Chief HR Office.. EVP, Chief HR Officer Dec 01 Sell 105 51,990 5,458,950 12/01/20
SALEKI-GERHARDT AZITA EVP, Operations EVP, Operations Nov 12 Option 24.21 4,800 116,208 118,667 11/12/20
SALEKI-GERHARDT AZITA EVP, Operations EVP, Operations Nov 12 Sell 93.61 4,800 449,328 113,867 11/12/20
GONZALEZ RICHARD A Chairman of the Boar.. Chairman of the Board and CEO Nov 12 Option 56.87 194,154 11,041,538 512,796 11/12/20
GONZALEZ RICHARD A Chairman of the Boar.. Chairman of the Board and CEO Nov 12 Sell 96.76 231,604 22,410,003 318,642 11/12/20